Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Specialized Risk Awareness

For decades, general health and science communication has served as the primary channel through which the public learns about medical risks and therapeutic interventions. This legacy framework typically presents information in a broad, population-level context, emphasizing preventive care and treatment efficacy. Within this tradition, audiences have become accustomed to receiving health guidance that is both accessible and grounded in established medical consensus. As this informational heritage evolves, a natural progression emerges toward more specialized domains of inquiry. The transition from general health awareness to specific exposure concerns requires careful attention to how risk is communicated across different contexts. In the realm of mass production, occupational exposure presents distinct challenges that differ markedly from consumer-oriented health messaging. Here, the focus shifts from voluntary therapeutic decisions to potential involuntary exposures within industrial environments. This pivot necessitates a reexamination of how risk information is framed and disseminated. While the legacy approach prioritizes broad accessibility, the occupational context demands precision regarding exposure pathways and duration. The bridge between these domains lies in recognizing that the same scientific principles governing general health communication must be adapted to address the unique circumstances of workplace settings, where exposure parameters and risk profiles differ substantially from those encountered in clinical or consumer contexts.

Bridging General Health Knowledge to Fosamax and ONJ

The general health framework provides a foundation for understanding therapeutic benefits and risks, but when a medication like Fosamax (alendronate) is linked to a serious adverse event such as osteonecrosis of the jaw (ONJ), a more focused examination is required. Fosamax is a bisphosphonate approved for osteoporosis and Paget's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism—inhibiting bone resorption—reduces fracture risk but also suppresses bone turnover, which can impair jawbone repair. This section bridges general health communication to the specific evidence linking Fosamax to ONJ, emphasizing the need for precise risk communication in both clinical and occupational settings.

Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously or following dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation of ONJ typically involves delayed healing after tooth extraction, local infection, or spontaneous exposure of bone. The condition is generally associated with invasive dental procedures such as tooth extraction, dental implants, or boney surgery, as well as local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Diagnosis relies on clinical examination and imaging, with multiscale characterization of jawbone providing comprehensive information to help understand jawbone-specific responses to bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve suppression of bone turnover. Bisphosphonates like alendronate inhibit osteoclast activity, which can impair the normal remodeling and repair processes in the jawbone, particularly after trauma or infection. This suppression may lead to accumulation of microdamage and reduced vascularity, predisposing the bone to necrosis. The jawbone's unique structure and high remodeling rate may make it especially vulnerable to these effects (https://pubmed.ncbi.nlm.nih.gov/40345077/). Risk factors for ONJ in patients taking Fosamax include invasive dental procedures, diagnosis of cancer, concomitant therapies such as chemotherapy, corticosteroids, or angiogenesis inhibitors, poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, although absolute risks remained low (approximately 0.05% after 5 years) and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Causation Considerations and Clinical Implications

Causation considerations for affected patients involve assessing the temporal relationship between Fosamax use and ONJ onset, excluding other causes such as cancer or radiotherapy, and evaluating risk factors. The label notes that ONJ can occur spontaneously but is generally associated with dental procedures or infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with duration of exposure, and the condition may resolve after drug discontinuation, though recurrence upon rechallenge supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, studies show that Fosamax use is associated with an increased risk of ONJ, particularly with longer treatment duration and in the presence of risk factors such as dental procedures. The prescribing information includes warnings about this risk, and patients should be monitored for symptoms. The absolute risk remains low, but the condition can be serious, and discontinuation of therapy may reduce risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption. A known adverse effect is osteonecrosis of the jaw (ONJ), where jawbone tissue dies. Studies show increased risk with longer use, especially after dental procedures. The prescribing information includes warnings about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, anemia, and ill-fitting dentures. Longer duration of Fosamax use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ diagnosed and what is the prognosis?

ONJ is diagnosed through clinical examination and imaging, such as multiscale characterization of jawbone (https://pubmed.ncbi.nlm.nih.gov/40345077/). Symptoms may resolve after stopping Fosamax, but recurrence can occur if rechallenged. Discontinuation of bisphosphonate may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.